<?xml version='1.0' encoding='utf-8'?>
<document id="31385001"><sentence text="A drug-drug interaction study to assess the potential effect of acid-reducing agent, lansoprazole, on quizartinib pharmacokinetics."><entity charOffset="85-97" id="DDI-PubMed.31385001.s1.e0" text="lansoprazole" /><entity charOffset="102-113" id="DDI-PubMed.31385001.s1.e1" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31385001.s1.e0" e2="DDI-PubMed.31385001.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s1.e0" e2="DDI-PubMed.31385001.s1.e1" /></sentence><sentence text="Quizartinib, a potent, selective FMS-like tyrosine kinase 3 (FLT3) inhibitor, is currently in phase 3 development for patients with FLT3-internal tandem duplication-mutated acute myeloid leukemia (AML)"><entity charOffset="0-11" id="DDI-PubMed.31385001.s2.e0" text="Quizartinib" /><entity charOffset="42-50" id="DDI-PubMed.31385001.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.31385001.s2.e0" e2="DDI-PubMed.31385001.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s2.e0" e2="DDI-PubMed.31385001.s2.e1" /></sentence><sentence text=" Acid-reducing agents (ARAs; e" /><sentence text="g" /><sentence text=", proton pump inhibitors) are frequently used during AML treatment" /><sentence text=" Since quizartinib demonstrates pH-dependent solubility, the effect of lansoprazole coadministration on pharmacokinetics (PK) of quizartinib tablet formulation was assessed"><entity charOffset="7-18" id="DDI-PubMed.31385001.s6.e0" text="quizartinib" /><entity charOffset="71-83" id="DDI-PubMed.31385001.s6.e1" text="lansoprazole" /><entity charOffset="129-140" id="DDI-PubMed.31385001.s6.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31385001.s6.e0" e2="DDI-PubMed.31385001.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s6.e0" e2="DDI-PubMed.31385001.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s6.e0" e2="DDI-PubMed.31385001.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31385001.s6.e1" e2="DDI-PubMed.31385001.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s6.e1" e2="DDI-PubMed.31385001.s6.e2" /></sentence><sentence text="" /><sentence text="An open-label, parallel-group study randomized 64 healthy adults to single-dose quizartinib 30 mg alone (reference) or lansoprazole (60 mg once daily, days 1-5) + single-dose quizartinib 30 mg (day 5) (test)"><entity charOffset="80-91" id="DDI-PubMed.31385001.s8.e0" text="quizartinib" /><entity charOffset="119-131" id="DDI-PubMed.31385001.s8.e1" text="lansoprazole" /><entity charOffset="175-186" id="DDI-PubMed.31385001.s8.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31385001.s8.e0" e2="DDI-PubMed.31385001.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s8.e0" e2="DDI-PubMed.31385001.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s8.e0" e2="DDI-PubMed.31385001.s8.e2" /><pair ddi="false" e1="DDI-PubMed.31385001.s8.e1" e2="DDI-PubMed.31385001.s8.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s8.e1" e2="DDI-PubMed.31385001.s8.e2" /></sentence><sentence text=" Plasma concentrations of quizartinib and its active metabolite, AC886, were measured to 504 h postdose; the effect of lansoprazole on quizartinib PK was assessed by analysis of variance"><entity charOffset="26-37" id="DDI-PubMed.31385001.s9.e0" text="quizartinib" /><entity charOffset="119-131" id="DDI-PubMed.31385001.s9.e1" text="lansoprazole" /><entity charOffset="135-149" id="DDI-PubMed.31385001.s9.e2" text="quizartinib PK" /><pair ddi="false" e1="DDI-PubMed.31385001.s9.e0" e2="DDI-PubMed.31385001.s9.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s9.e0" e2="DDI-PubMed.31385001.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s9.e0" e2="DDI-PubMed.31385001.s9.e2" /><pair ddi="false" e1="DDI-PubMed.31385001.s9.e1" e2="DDI-PubMed.31385001.s9.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s9.e1" e2="DDI-PubMed.31385001.s9.e2" /></sentence><sentence text="" /><sentence text="Quizartinib geometric mean ratios (test/reference) and 90% confidence intervals for maximum observed plasma concentration (Cmax), area under the concentration-time curve to last measurable drug concentration (AUClast), and AUC to infinity were 86"><entity charOffset="0-11" id="DDI-PubMed.31385001.s11.e0" text="Quizartinib" /></sentence><sentence text="11% (78" /><sentence text="4%, 94" /><sentence text="6%), 93" /><sentence text="96% (79" /><sentence text="6%, 110" /><sentence text="9%), and 95" /><sentence text="30% (80" /><sentence text="2%, 113" /><sentence text="3%), respectively" /><sentence text=" Comparisons showed a modest decrease in quizartinib absorption when co-administered with lansoprazole, with lower limits for Cmax and AUClast just below 80-125% limits"><entity charOffset="41-52" id="DDI-PubMed.31385001.s21.e0" text="quizartinib" /><entity charOffset="90-102" id="DDI-PubMed.31385001.s21.e1" text="lansoprazole" /><pair ddi="false" e1="DDI-PubMed.31385001.s21.e0" e2="DDI-PubMed.31385001.s21.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s21.e0" e2="DDI-PubMed.31385001.s21.e1" /></sentence><sentence text=" Treatment-emergent adverse events were mild or moderate; the most frequent in either treatment group were headache [quizartinib alone: (n = 3) 10%], upper respiratory tract infection [quizartinib alone: (n = 2) 6" /><sentence text="7%; lansoprazole + quizartinib: (n = 3) 9" /><sentence text="1%], and muscle tightness [quizartinib alone: (n = 2) 6" /><sentence text="7%]" /><sentence text="" /><sentence text="Concomitant lansoprazole had minimal effect on quizartinib PK as a formulated tablet, indicating that quizartinib can be administered with ARAs"><entity charOffset="12-24" id="DDI-PubMed.31385001.s27.e0" text="lansoprazole" /><entity charOffset="47-61" id="DDI-PubMed.31385001.s27.e1" text="quizartinib PK" /><entity charOffset="102-113" id="DDI-PubMed.31385001.s27.e2" text="quizartinib" /><pair ddi="false" e1="DDI-PubMed.31385001.s27.e0" e2="DDI-PubMed.31385001.s27.e0" /><pair ddi="false" e1="DDI-PubMed.31385001.s27.e0" e2="DDI-PubMed.31385001.s27.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s27.e0" e2="DDI-PubMed.31385001.s27.e2" /><pair ddi="false" e1="DDI-PubMed.31385001.s27.e1" e2="DDI-PubMed.31385001.s27.e1" /><pair ddi="false" e1="DDI-PubMed.31385001.s27.e1" e2="DDI-PubMed.31385001.s27.e2" /></sentence><sentence text="" /></document>